ARIA Profile
ARIAD Pharmaceuticals, Inc. (ARIA) was a biopharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of cancer. The company's products were designed to target specific proteins and pathways involved in cancer cell growth and survival.
ARIAD Pharmaceuticals' lead product was called Iclusig (ponatinib), which was approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of certain types of leukemia. The company also had a number of other product candidates in various stages of development for the treatment of lung cancer, breast cancer, and other types of cancer.
ARIAD Pharmaceuticals was founded in 1991 and was headquartered in Cambridge, Massachusetts. In 2017, the company was acquired by Takeda Pharmaceutical Company Limited, a global pharmaceutical company based in Japan. As a result of the acquisition, ARIAD Pharmaceuticals is now a wholly owned subsidiary of Takeda and is no longer a publicly traded company.
|
